Steven G Reed

Summary

Affiliation: Corixa Corporation
Country: USA

Publications

  1. ncbi Vaccines for parasitic and bacterial diseases
    Steven G Reed
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Curr Opin Immunol 15:456-60. 2003
  2. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
  3. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
  4. pmc Optimized subunit vaccine protects against experimental leishmaniasis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:7036-45. 2009
  5. pmc Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection
    Vanitha S Raman
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, Washington 98104, USA
    Infect Immun 77:5623-30. 2009
  6. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
  7. pmc Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:223-33. 2009
  8. doi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
  9. doi Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 31:813-9. 2013
  10. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012

Collaborators

Detail Information

Publications121 found, 100 shown here

  1. ncbi Vaccines for parasitic and bacterial diseases
    Steven G Reed
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Curr Opin Immunol 15:456-60. 2003
    ..There are indications both in animal models and in patients that vaccines may be used not only to protect but also to treat leishmania infections...
  2. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
    ..Thus, there is renewed optimism for the potential of developing new and improved TB vaccines...
  3. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  4. pmc Optimized subunit vaccine protects against experimental leishmaniasis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:7036-45. 2009
    ..This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists...
  5. pmc Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection
    Vanitha S Raman
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, Washington 98104, USA
    Infect Immun 77:5623-30. 2009
    ....
  6. ncbi Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41
    Yasir A W Skeiky
    Corixa Corporation, Seattle, WA, USA
    Vaccine 23:3937-45. 2005
    ....
  7. pmc Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:223-33. 2009
    ..8 formulated in either AS02A or AS01B Adjuvant Systems. These results demonstrate that T-cell screening of the Mtb genome can be used to identify CD4+ T-cell antigens that are candidates for vaccine development...
  8. doi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
    ....
  9. doi Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 31:813-9. 2013
    ..leprae-induced inflammation in mice. We are using these data to develop new vaccine initiatives for the continued and long-term control of leprosy...
  10. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  11. doi Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
    Ryan C Anderson
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Colloids Surf B Biointerfaces 75:123-32. 2010
    ....
  12. pmc Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells
    Rhea N Coler
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:4648-54. 2007
    ..The Leish-111f+MPL-SE product we report here is the first defined vaccine for leishmaniasis in human clinical trials and has completed phase 1 and 2 safety and immunogenicity testing in normal, healthy human subjects...
  13. pmc Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 25:7450-8. 2007
    ..The results indicate that SMT/MPL-SE can be an effective vaccine candidate for use against VL...
  14. pmc Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
    Mark T Orr
    Infectious Disease Research Institute, Seattle 98104, USA
    J Control Release 172:190-200. 2013
    ..These results demonstrate that there are multiple solutions for an effective formulation of a novel TB vaccine candidate that enhances both TH1 generation and protective efficacy. ..
  15. pmc Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
    ....
  16. pmc Antigen-specific T-cell responses of leprosy patients
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1659-65. 2008
    ..Our results indicate several potential candidate antigens which may be useful for either leprosy diagnosis or vaccination and demonstrate the utility of leprosy WBA that can be applied broadly in clinical or field settings...
  17. pmc KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 18:1118-24. 2011
    ..major, responsible for cutaneous leishmaniasis. The results demonstrate the feasibility of producing a practical, cost-effective leishmaniasis vaccine capable of protecting both humans and dogs against multiple Leishmania species...
  18. pmc Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
    Hillarie Plessner Windish
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 29:7842-8. 2011
    ..ID87/GLA-SE appears to be a promising new vaccine candidate that warrants further development...
  19. pmc MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
    Mark T Orr
    Infectious Disease Research Institute, Seattle, WA, USA
    Eur J Immunol 43:2398-408. 2013
    ..Thus engagement of both the MyD88 and TRIF signaling pathways are essential for the effective adjuvant activity of this TLR4 agonist...
  20. ncbi Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process
    Sandeep Mukherjee
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 175:5298-305. 2005
    ....
  21. pmc Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 27:2884-90. 2009
    ..Mice immunized with the SMT/MPL-SE vaccine developed significantly smaller lesions following ear challenge with L. major. These results suggest that SMT is a promising vaccine antigen for multiple forms of leishmaniasis...
  22. ncbi Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
    ..tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB...
  23. pmc Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98102, USA
    J Immunol 191:2514-25. 2013
    ..Our findings provide insight into the development of vaccines not only for tuberculosis, but other diseases requiring T cell immunity. ..
  24. pmc The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
    ..These results highlight the importance of properly formulating subunit vaccines with effective adjuvants for use against tuberculosis...
  25. pmc Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay
    Lance K Ching
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    J Immunol Methods 373:54-62. 2011
    ..Overall, the QuantiGene platform is reliable, reproducible, and sensitive. These agonists have the potential to be used as adjuvant components in vaccines against various pathogens...
  26. ncbi Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  27. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  28. ncbi Serum antibodies to lipophilin B detected in late stage breast cancer patients
    Darrick Carter
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, Washington 98104, USA
    Clin Cancer Res 9:749-54. 2003
    ..A polymorphism identified in Lipophilin B did not appear to influence human sera reactivity. The data indicate that humoral immune responses to lipophilin B may serve as a diagnostic indicator, particularly for breast cancer...
  29. pmc Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys
    Steven G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 106:2301-6. 2009
    ....
  30. pmc Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  31. pmc Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 69:4103-8. 2001
    ..The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis...
  32. ncbi Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning
    P Probst
    Corixa Corporation, Seattle, WA 98104, USA
    J Immunol 166:498-505. 2001
    ..Ags identified by T cells from immune donors might constitute potential vaccine candidates for leishmaniasis...
  33. doi Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses
    Anthony L Desbien
    Infectious Disease Research Institute, Seattle, WA
    Biotechniques 54:345-8. 2013
    ..We are advancing this technology as a platform for rapid, simple, high-throughput assessment of homologous and heterologous antibody responses to influenza disease and vaccination...
  34. doi Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Pharm Dev Technol 16:511-9. 2011
    ..Substitution of naturally derived egg phosphatidylcholine with synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) produced an emulsion with similar physicochemical properties and stability...
  35. pmc A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    Sci Transl Med 2:53ra74. 2010
    ....
  36. pmc Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 74:3939-45. 2006
    ..Our results suggest that TR regions from the novel L. infantum proteins identified in this study are immunodominant B-cell epitopes and may represent good candidates for serodiagnosis of VL...
  37. pmc Insight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 18:254-9. 2011
    ..leprae infection but also indicate considerable variability in the development of antigen-specific antibodies. Our data suggest that a combination of antigens is likely required to provide accurate and early leprosy diagnosis...
  38. pmc Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vet Parasitol 160:215-20. 2009
    ..In addition, we show a correlation between antibody titers to several antigens and severity of clinical symptoms during canine VL...
  39. pmc Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    FEMS Immunol Med Microbiol 55:258-70. 2009
    ..trachomatis. Some of the vaccines prevented bacterial shedding and colonization of the upper genital tract to varying degrees by mechanisms that may include CD4+ T cells...
  40. doi Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Influenza Other Respir Viruses 7:815-26. 2013
    ..However, few reports have been published that systematically evaluate the in vitro stability and in vivo adjuvant effects of different emulsion components...
  41. pmc Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear
    Malcolm S Duthie
    Infectious Disease Research Institute, Suite 400, 1124 Columbia St, Seattle, WA 98104, USA
    Infect Immun 75:5290-7. 2007
    ..These results indicate the utility of intradermal ear infection for both induction and understanding of the immune response during M. leprae infection and the identification or testing of new leprosy treatments...
  42. pmc Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
    ..This highlights the need to explore different routes of immunization based on the adjuvant formulations used...
  43. pmc Immunological dominance of Trypanosoma cruzi tandem repeat proteins
    Yasuyuki Goto
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 76:3967-74. 2008
    ..cruzi strains with regard to induced immunological responses, host susceptibility, disease outcomes, and pathogenicity...
  44. pmc Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis
    Malcolm S Duthie
    Protein Advances Inc, 1102 Columbia St, Seattle, WA 98104, USA
    Clin Vaccine Immunol 17:298-303. 2010
    ....
  45. ncbi P704P, P712P, and P775P: A genomic cluster of prostate-specific genes
    John A Stolk
    Corixa Corporation, Seattle, Washington 98104, USA
    Prostate 60:214-26. 2004
    ..Such understanding will likely result in the development of promising new markers for screening, diagnosis, and prognosis, as well as potential therapeutic approaches for combating this disease...
  46. pmc Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis
    J R Webb
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 66:4208-14. 1998
    ..Recombinant MTB12 protein elicited in vitro proliferative responses from the peripheral blood mononuclear cells of a number of purified protein derivative-positive (PPD+) human donors but not from PPD- donors...
  47. pmc Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice
    A Campos-Neto
    Infectious Disease Research Institute Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 70:2828-36. 2002
    ....
  48. pmc Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 19:1633-40. 2012
    ..Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose...
  49. pmc Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  50. pmc Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex
    Yasuyuki Goto
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Infect Immun 75:846-51. 2007
    ..0070, LinJ25.1100, LinJ27.0400, and LinJ29.0110, which were from the 42 uncharacterized proteins, are also antigenic. The results suggest the validity of this approach for identifying leishmanial antigens of serological significance...
  51. doi Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
    ..Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model...
  52. ncbi Development of a leishmaniasis vaccine: the importance of MPL
    Steven G Reed
    Corixa Corporation, Seattle, WA, USA
    Expert Rev Vaccines 2:239-52. 2003
    ..This vaccine has potential application in both the prevention and treatment of leishmaniasis...
  53. pmc Use of protein antigens for early serological diagnosis of leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 14:1400-8. 2007
    ..A serological diagnostic test capable of identifying and allowing treatment of early-stage leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  54. pmc Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 15:1590-7. 2008
    ..A serological diagnostic test capable of identifying and allowing treatment of leprosy could reduce transmission, prevent functional disabilities and stigmatizing deformities, and facilitate leprosy eradication...
  55. pmc Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae
    Antonio Campos-Neto
    Infectious Disease Research Institute, Seattle, Washington, USA
    Infect Immun 71:5065-76. 2003
    ....
  56. pmc Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis
    Vanitha S Raman
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 185:1701-10. 2010
    ..Our data help to define a correlate of protection during active infection and indicate TLR synergy to be a potentially valuable tool in treating intracellular infections...
  57. ncbi TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
    Christopher B Fox
    Infectious Disease Research Institute, 1616 Eastlake Avenue, Suite 400, Seattle, WA 98102, USA Electronic address
    Vaccine 31:5848-55. 2013
    ..g. TLR ligands) on the resulting immune responses to adjuvanted vaccines and may play a critical role for combating diseases where T cell immunity is advantageous. ..
  58. pmc Rapid Quantitative Serological Test for Detection of Infection with Mycobacterium leprae, the Causative Agent of Leprosy
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Clin Microbiol 52:613-9. 2014
    ..Taken together, these data indicate that the NDO-LID/Smart Reader system can assist in the diagnosis and monitoring of MB leprosy and can detect a significant number of earlier-stage infections. ..
  59. pmc Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice
    Sandeep Mukherjee
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Diagn Lab Immunol 11:280-6. 2004
    ..The immediate availability of the antigen at a time point in which the patient's immune system is still competent would lead to a secondary immune response to U1 that persists for months in the patient's serum...
  60. pmc A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 5:e13677. 2010
    ..These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines...
  61. ncbi Expression and purification of immunologically reactive DPPD, a recombinant Mycobacterium tuberculosis skin test antigen, using Mycobacterium smegmatis and Escherichia coli host cells
    Chao Liu
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Can J Microbiol 50:97-105. 2004
    ..Because the DPPD gene is present only in the tuberculosis-complex organisms of the Mycobacterium genus, these highly purified molecules should be helpful in identifying individuals sensitized with tubercle bacilli...
  62. ncbi IL-10 mediates susceptibility to Trypanosoma cruzi infection
    S G Reed
    Infectious Disease Research Institute, Seattle, WA 98109
    J Immunol 153:3135-40. 1994
    ..cruzi by the administration of neutralizing anti-IL-10 mAb. This study demonstrated an important and perhaps essential role of IL-10 in mediating in vivo susceptibility to T. cruzi infection...
  63. pmc Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization
    Mark T Orr
    Infectious Disease Research Institute, Seattle, WA 98102, USA Electronic address
    J Control Release 177:20-6. 2014
    ....
  64. pmc Advances and hurdles on the way toward a leprosy vaccine
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA USA
    Hum Vaccin 7:1172-83. 2011
    ..We summarize and discuss leprosy vaccine strategies that have been deployed previously and discuss those strategies that are currently being developed to augment recent breakthroughs in leprosy control...
  65. pmc The development and clinical evaluation of second-generation leishmaniasis vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 30:134-41. 2012
    ..Finally, potential refinements and surrogate markers that could expedite the introduction of a vaccine that can limit the severity and incidence of leishmaniasis are discussed...
  66. doi Targeting TLRs expands the antibody repertoire in response to a malaria vaccine
    Steven R Wiley
    Imdaptive Inc, 3010 Northwest 56th Street, Seattle, WA 98107, USA
    Sci Transl Med 3:93ra69. 2011
    ....
  67. doi Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Subcell Biochem 53:303-21. 2010
    ..Moreover, the formulation of TLR4 agonists has been shown to significantly affect the type and magnitude of elicited immune response. TLR4 agonists comprise a promising class of adjuvants for safe and effective vaccines...
  68. pmc Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value
    Gregory C Ireton
    Infectious Disease Research Institute, 1124 Columbia Street, Seattle, WA 98104, USA
    Clin Vaccine Immunol 17:1539-47. 2010
    ....
  69. pmc Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay
    Raymond L Houghton
    InBios International, Inc, Seattle, WA 98104, USA
    Clin Vaccine Immunol 16:515-20. 2009
    ..2, with two additional sequences for peptide 1 and Kmp-11. The latter, when evaluated in a dipstick assay with consensus positive sera, had a sensitivity of 99.2% and a specificity of 99.1%...
  70. ncbi Prostein expression is highly restricted to normal and malignant prostate tissues
    Michael Kalos
    Corixa Corporation, Seattle, Washington 98104, USA
    Prostate 60:246-56. 2004
    ..A murine monoclonal antibody was developed, characterized, and used to evaluate the expression of prostein protein in prostatic, other normal tissue and tumor samples...
  71. ncbi Second-generation vaccines against leishmaniasis
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Trends Parasitol 21:244-9. 2005
    ..In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis...
  72. pmc Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
    J R Webb
    Infectious Disease Research Institute, University of Washington, Seattle, Washington, USA
    Infect Immun 66:3279-89. 1998
    ..Together, these data suggest that the TSA protein may be useful as a component of a subunit vaccine against leishmaniasis...
  73. pmc Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis
    R C Hendrickson
    Corixa Corporation, Seattle Washington 98140, USA
    J Clin Microbiol 38:2354-61. 2000
    ..Together, these results demonstrate that Mtb81 may be a promising complementary antigen for the serodiagnosis of TB...
  74. ncbi The potential for vaccination in leprosy elimination: new tools for targeted interventions
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Mem Inst Oswaldo Cruz 107:190-6. 2012
    ....
  75. ncbi Taking toll: lipid A mimetics as adjuvants and immunomodulators
    David H Persing
    Corixa, Suite 200, 1124 Columbia Street, Seattle, WA 98104, USA
    Trends Microbiol 10:S32-7. 2002
    ..Novel approaches to vaccine development could benefit from taking full advantage of the effects of these compounds on innate and adaptive responses...
  76. ncbi Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera
    Craig H Day
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington, WA 98104, USA
    Oncogene 21:7114-20. 2002
    ....
  77. pmc Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Ste 400, Seattle, WA 98104, USA
    Clin Vaccine Immunol 18:1378-86. 2011
    ..tuberculosis proteins during the course of TB therapy might be a promising path toward the development of a test of cure and warrants further validation in larger cohorts of pulmonary TB patients...
  78. doi New horizons in adjuvants for vaccine development
    Steven G Reed
    Infectious Disease Research Institute, 1124 Columbia St Suite 400, Seattle, WA 98104, USA
    Trends Immunol 30:23-32. 2009
    ..In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants...
  79. ncbi Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Colloids Surf B Biointerfaces 65:98-105. 2008
    ..It is shown that oil-in-water emulsions using animal-derived components can be substituted with synthetic or plant-derived materials while still exhibiting satisfactory physicochemical and biological properties...
  80. doi Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
    ....
  81. ncbi A high-throughput methodology for identifying molecular targets overexpressed in lung cancers
    Tongtong Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, WA, USA
    Methods Mol Med 75:177-88. 2003
  82. ncbi Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer
    Darrick Carter
    Department of Antigen Discovery, Corixa Corp, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Biochemistry 41:6714-22. 2002
    ..This work describes the biochemistry of the mammaglobin/lipophilin B complex and lays the framework for use of this complex as a novel protein-based serological marker for breast cancer...
  83. ncbi Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays
    Yuqiu Jiang
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington, WA 98104, USA
    Oncogene 21:2270-82. 2002
    ..These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer...
  84. ncbi Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in patients with treated or untreated Chagas' disease
    R L Houghton
    Corixa Corporation, Seattle, WA 98104
    J Infect Dis 181:325-30. 2000
    ..The results indicate that multiepitope antigens provide a more sensitive and specific alternative to lysate for detection of anti-T. cruzi antibodies, as required for developing blood screening assays...
  85. ncbi Identification and characterization of prostein, a novel prostate-specific protein
    J Xu
    Corixa Corp, Seattle Washington 98104, USA
    Cancer Res 61:1563-8. 2001
    ..These results validate prostein as a prostate-specific marker with potential utility in the diagnosis and treatment of prostate cancer...
  86. ncbi A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells
    P Probst
    Infectious Disease Research Institute, Seattle, WA, USA
    Eur J Immunol 27:2634-42. 1997
    ..These immunomodulatory characteristics of LeIF might be excellent properties for a Th1-type adjuvant...
  87. pmc Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 65:5368-70. 1997
    ....
  88. ncbi A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy
    R L Houghton
    Corixa Corp, Seattle, Washington 98104, USA
    J Infect Dis 177:1339-44. 1998
    ..In contrast, most patients who clinically relapsed showed increased antibody titers to rK39. These data demonstrate the diagnostic and prognostic utility of rK39 in detecting active visceral leishmaniasis...
  89. ncbi LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
    Y A Skeiky
    Corixa Corporation, Seattle, WA 98104, USA
    J Immunol 161:6171-9. 1998
    ..major. Thus, our results suggest the potential of LeIF as a Th1-type adjuvant and as a therapeutic and prophylactic vaccine Ag for leishmaniasis when used with other leishmanial Ags...
  90. ncbi A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera
    R L Houghton
    Corixa Corporation, Seattle, WA 98104, USA
    J Infect Dis 179:1226-34. 1999
    ..These studies show that peptides and recombinants containing multiple repeat epitopes are powerful tools for developing assays for T. cruzi antibody detection and have direct application in blood screening...
  91. pmc Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:2941-50. 1999
    ..The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M.tuberculosis...
  92. pmc Serological expression cloning of novel immunoreactive antigens of Babesia microti
    M J Lodes
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 68:2783-90. 2000
    ..Western blot analysis with the resulting recombinant proteins indicated that these antigens were targets of humoral immune responses during B. microti infection in humans...
  93. pmc Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells
    M R Alderson
    Department of Immunology, Corixa Corporation, Seattle, Washington 98104, USA
    J Exp Med 191:551-60. 2000
    ..9A. The direct identification of antigens using T cells from immune donors will undoubtedly be critical for the development of vaccines to several intracellular pathogens...
  94. pmc Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 38:3285-90. 2000
    ..rCFP-10 could also contribute to the development of a recombinant T-cell diagnostic test capable of detecting exposure to M. tuberculosis...
  95. pmc Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:3998-4007. 1999
    ..MTB32A, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during Mycobacterium spp. infection is discussed...
  96. pmc Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins
    M J Lodes
    Corixa Corporation, 1124 Columbia St, Suite 200, Seattle, WA 98104, USA
    J Clin Microbiol 39:2466-76. 2001
    ..2% (23 of 27) of acute-phase patient serum samples are detected, indicating the potential of these antigens for use in the development of a rapid serologic assay for the detection of E. phagocytophila infection...
  97. ncbi Detection of mammaglobin in the sera of patients with breast cancer
    G R Fanger
    Corixa Corporation, Department of Antigen Discovery, Seattle, WA 98104, USA
    Tumour Biol 23:212-21. 2002
    ..Thus, mammaglobin, which is overexpressed and secreted from breast carcinoma cells, is detectable in sera of patients with breast cancer and may provide a rapid screening test for the diagnosis and management of breast cancer...
  98. pmc Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen
    M J Lodes
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 39:2485-93. 2001
    ..tuberculosis infection when it is combined with other known immunodominant antigens, such as the 38-kDa antigen...
  99. ncbi Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells
    R L Houghton
    Corixa Corporation, 1124 Columbia St, Ste 200, Seattle, WA 98104, USA
    Mol Diagn 6:79-91. 2001
    ..We used a combination of genetic subtraction, silicon DNA microarray analysis, and quantitative PCR to identify tissue- and tumor-specific genes as diagnostic targets for breast cancer...
  100. pmc L523S, an RNA-binding protein as a potential therapeutic target for lung cancer
    T Wang
    Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, WA 98104, USA
    Br J Cancer 88:887-94. 2003
    ..Collectively, our studies suggest that L523S may be an important marker of malignant progression in human lung cancer, and further suggest that treatment approaches based on L523S as an immunogenic target are worthy of pursuit...